NCT07415980 is a Phase 1, PHASE2 clinical trial of Polatuzumab Vedotin in Double Expressor DLBCL, sponsored by Sun Yat-sen University.

Who is sponsoring NCT07415980?

NCT07415980 is sponsored by Sun Yat-sen University.

What drugs are being tested in NCT07415980?

Interventions in NCT07415980: Polatuzumab Vedotin, Rituximab (R), Chidamide.

What condition does NCT07415980 study?

NCT07415980 studies Double Expressor DLBCL.

Is NCT07415980 still recruiting?

NCT07415980 is currently not yet recruiting. Last updated 17 February 2026.

Last reviewed 2026-02-17 · How we verify

NCT07415980

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase Ib/II Study of Polatuzumab Vedotin in Combination With Rituximab and Chidamide in Newly Diagnosed Elderly Patients With Double-Expressor DLBCL

Not yet recruiting Phase 1, PHASE2 Last updated 17 February 2026

What this trial tests

Phase 1, PHASE2 trial testing Polatuzumab Vedotin in Double Expressor DLBCL in 68 participants. Not yet recruiting.

Timeline

1 April 2026

Primary endpoint
1 April 2028

1 April 2031

Quick facts

Lead sponsor	Sun Yat-sen University
Phase	Phase 1, PHASE2
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	68
Start date	1 April 2026
Primary completion	1 April 2028
Estimated completion	1 April 2031

Drugs / interventions tested

Polatuzumab Vedotin (POLATUZUMAB VEDOTIN) — full drug profile →
Rituximab (R) — full drug profile →
Chidamide — full drug profile →

Conditions studied

Double Expressor DLBCL — all drugs for Double Expressor DLBCL →

Sponsor

Sun Yat-sen University

Who can join

60 and older, any sex, with Double Expressor DLBCL. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a single-arm, prospective, multicenter, open-label phase Ib/II study to evaluate the safety and efficacy of polatuzumab vedotin in combination with rituximab and chidamide in previously untreated elderly patients with MYC/BCL2 double-expressor diffuse large B-cell lymphoma.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Polatuzumab Vedotin

Trials testing the same drug.

NCT07397832 — CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCL · Phase 2 · recruiting
NCT07122609 — Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BT · Phase 2 · not yet recruiting
NCT07034508 — A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IP · Phase 2 · not yet recruiting
NCT07012980 — Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL · Phase 2 · not yet recruiting
NCT06730542 — Zanubrutinib in Combination With Pola-R-CHP and High-dose Methotrexate in Patients With Secondary CNS Lymphoma · Phase 1 · recruiting

Other recruiting trials for Double Expressor DLBCL

Currently open trials in the same condition.

NCT06736613 — A Study of Circulating Tumor DNA (ctDNA) Testing for People With B-Cell Lymphoma · Phase 2 · recruiting

Other Sun Yat-sen University trials

Trials by the same sponsor.

NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07415980 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
Last refreshed: 17 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07415980.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing